ID   REN3B_HUMAN             Reviewed;         483 AA.
AC   Q9BZI7; D3DWI3; D3DWI4; Q0VAK8; Q9H1J0;
DT   01-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   07-APR-2021, entry version 175.
DE   RecName: Full=Regulator of nonsense transcripts 3B;
DE   AltName: Full=Nonsense mRNA reducing factor 3B;
DE   AltName: Full=Up-frameshift suppressor 3 homolog B;
DE            Short=hUpf3B;
DE   AltName: Full=Up-frameshift suppressor 3 homolog on chromosome X;
DE            Short=hUpf3p-X;
GN   Name=UPF3B; Synonyms=RENT3B, UPF3X;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION IN NONSENSE-MEDIATED MRNA
RP   DECAY, INTERACTION WITH UPF1 AND UPF2, AND SUBCELLULAR LOCATION.
RX   PubMed=11163187; DOI=10.1016/s0092-8674(00)00214-2;
RA   Lykke-Andersen J., Shu M.-D., Steitz J.A.;
RT   "Human Upf proteins target an mRNA for nonsense-mediated decay when bound
RT   downstream of a termination codon.";
RL   Cell 103:1121-1131(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH UPF2, MUTAGENESIS
RP   OF 53-VAL--LEU-58 AND 117-TYR--PHE-119, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=11113196; DOI=10.1128/mcb.21.1.209-223.2001;
RA   Serin G., Gersappe A., Black J.D., Aronoff R., Maquat L.E.;
RT   "Identification and characterization of human orthologues to Saccharomyces
RT   cerevisiae Upf2 protein and Upf3 protein (Caenorhabditis elegans SMG-4).";
RL   Mol. Cell. Biol. 21:209-223(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH RBM8A, IDENTIFICATION IN A POST-SPLICING MRNP COMPLEX,
RP   ASSOCIATION WITH THE EJC COMPLEX, AND RNA-BINDING.
RX   PubMed=11546873; DOI=10.1126/science.1062829;
RA   Kim V.N., Kataoka N., Dreyfuss G.;
RT   "Role of the nonsense-mediated decay factor hUpf3 in the splicing-dependent
RT   exon-exon junction complex.";
RL   Science 293:1832-1836(2001).
RN   [6]
RP   IDENTIFICATION IN A POST-SPLICING MRNP COMPLEX, AND ASSOCIATION WITH THE
RP   EJC COMPLEX.
RX   PubMed=11546874; DOI=10.1126/science.1062786;
RA   Lykke-Andersen J., Shu M.-D., Steitz J.A.;
RT   "Communication of the position of exon-exon junctions to the mRNA
RT   surveillance machinery by the protein RNPS1.";
RL   Science 293:1836-1839(2001).
RN   [7]
RP   FUNCTION IN NONSENSE-MEDIATED MRNA DECAY, INTERACTION WITH RBM8A, AND
RP   MUTAGENESIS OF ARG-430; ARG-432; 434-LYS--ARG-447; LYS-434; ASP-435;
RP   ARG-436 AND LEU-441.
RX   PubMed=12718880; DOI=10.1016/s1097-2765(03)00142-4;
RA   Gehring N.H., Neu-Yilik G., Schell T., Hentze M.W., Kulozik A.E.;
RT   "Y14 and hUpf3b form an NMD-activating complex.";
RL   Mol. Cell 11:939-949(2003).
RN   [8]
RP   INTERACTION WITH EST1A.
RX   PubMed=12554878; DOI=10.1261/rna.2137903;
RA   Chiu S.-Y., Serin G., Ohara O., Maquat L.E.;
RT   "Characterization of human Smg5/7a: a protein with similarities to
RT   Caenorhabditis elegans SMG5 and SMG7 that functions in the
RT   dephosphorylation of Upf1.";
RL   RNA 9:77-87(2003).
RN   [9]
RP   FUNCTION IN NONSENSE-MEDIATED MRNA DECAY, ASSOCIATION WITH THE EJC COMPLEX,
RP   AND IDENTIFICATION IN A COMPLEX WITH UPF2 AND RNPS1.
RX   PubMed=16209946; DOI=10.1016/j.molcel.2005.08.012;
RA   Gehring N.H., Kunz J.B., Neu-Yilik G., Breit S., Viegas M.H., Hentze M.W.,
RA   Kulozik A.E.;
RT   "Exon-junction complex components specify distinct routes of nonsense-
RT   mediated mRNA decay with differential cofactor requirements.";
RL   Mol. Cell 20:65-75(2005).
RN   [10]
RP   FUNCTION IN NONSENSE-MEDIATED MRNA DECAY, FUNCTION IN TRANSLATION
RP   STIMULATION, ASSOCIATION WITH THE EJC COMPLEX, AND MUTAGENESIS OF ARG-432.
RX   PubMed=16601204; DOI=10.1261/rna.12506;
RA   Kunz J.B., Neu-Yilik G., Hentze M.W., Kulozik A.E., Gehring N.H.;
RT   "Functions of hUpf3a and hUpf3b in nonsense-mediated mRNA decay and
RT   translation.";
RL   RNA 12:1015-1022(2006).
RN   [11]
RP   FUNCTION, AND RECONSTITUTION OF THE EJC CORE-UPF COMPLEX.
RX   PubMed=18066079; DOI=10.1038/nsmb1330;
RA   Chamieh H., Ballut L., Bonneau F., Le Hir H.;
RT   "NMD factors UPF2 and UPF3 bridge UPF1 to the exon junction complex and
RT   stimulate its RNA helicase activity.";
RL   Nat. Struct. Mol. Biol. 15:85-93(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-169, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   INTERACTION WITH CPSF6.
RX   PubMed=19864460; DOI=10.1091/mbc.e09-05-0389;
RA   Ruepp M.D., Aringhieri C., Vivarelli S., Cardinale S., Paro S.,
RA   Schuemperli D., Barabino S.M.;
RT   "Mammalian pre-mRNA 3' end processing factor CF I m 68 functions in mRNA
RT   export.";
RL   Mol. Biol. Cell 20:5211-5223(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-169, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-198, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-169 AND SER-310, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-169 AND SER-310, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   IDENTIFICATION IN THE EXON JUNCTION COMPLEX.
RX   PubMed=23917022; DOI=10.4161/rna.25827;
RA   Singh K.K., Wachsmuth L., Kulozik A.E., Gehring N.H.;
RT   "Two mammalian MAGOH genes contribute to exon junction complex composition
RT   and nonsense-mediated decay.";
RL   RNA Biol. 10:1291-1298(2013).
RN   [20]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-447, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 50-140 IN COMPLEX WITH UPF2,
RP   RNA-BINDING, AND MUTAGENESIS OF LYS-52 AND ARG-56.
RX   PubMed=15004547; DOI=10.1038/nsmb741;
RA   Kadlec J., Izaurralde E., Cusack S.;
RT   "The structural basis for the interaction between nonsense-mediated mRNA
RT   decay factors UPF2 and UPF3.";
RL   Nat. Struct. Mol. Biol. 11:330-337(2004).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 424-483 IN COMPLEX WITH EIF4A3;
RP   MAGOH; RBM8A AND CASC3, AND MUTAGENESIS OF ARG-436; TYR-442; ARG-447;
RP   ARG-449 AND ARG-451.
RX   PubMed=20479275; DOI=10.1073/pnas.1000993107;
RA   Buchwald G., Ebert J., Basquin C., Sauliere J., Jayachandran U., Bono F.,
RA   Le Hir H., Conti E.;
RT   "Insights into the recruitment of the NMD machinery from the crystal
RT   structure of a core EJC-UPF3b complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:10050-10055(2010).
RN   [23]
RP   VARIANT MRXS14 ASP-160.
RX   PubMed=17704778; DOI=10.1038/ng2100;
RA   Tarpey P.S., Raymond F.L., Nguyen L.S., Rodriguez J., Hackett A.,
RA   Vandeleur L., Smith R., Shoubridge C., Edkins S., Stevens C., O'Meara S.,
RA   Tofts C., Barthorpe S., Buck G., Cole J., Halliday K., Hills K., Jones D.,
RA   Mironenko T., Perry J., Varian J., West S., Widaa S., Teague J., Dicks E.,
RA   Butler A., Menzies A., Richardson D., Jenkinson A., Shepherd R., Raine K.,
RA   Moon J., Luo Y., Parnau J., Bhat S.S., Gardner A., Corbett M., Brooks D.,
RA   Thomas P., Parkinson-Lawrence E., Porteous M.E., Warner J.P., Sanderson T.,
RA   Pearson P., Simensen R.J., Skinner C., Hoganson G., Superneau D.,
RA   Wooster R., Bobrow M., Turner G., Stevenson R.E., Schwartz C.E.,
RA   Futreal P.A., Srivastava A.K., Stratton M.R., Gecz J.;
RT   "Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex,
RT   cause syndromic and nonsyndromic mental retardation.";
RL   Nat. Genet. 39:1127-1133(2007).
CC   -!- FUNCTION: Involved in nonsense-mediated decay (NMD) of mRNAs containing
CC       premature stop codons by associating with the nuclear exon junction
CC       complex (EJC) and serving as link between the EJC core and NMD
CC       machinery. Recruits UPF2 at the cytoplasmic side of the nuclear
CC       envelope and the subsequent formation of an UPF1-UPF2-UPF3 surveillance
CC       complex (including UPF1 bound to release factors at the stalled
CC       ribosome) is believed to activate NMD. In cooperation with UPF2
CC       stimulates both ATPase and RNA helicase activities of UPF1. Binds
CC       spliced mRNA upstream of exon-exon junctions. In vitro, stimulates
CC       translation; the function is independent of association with UPF2 and
CC       components of the EJC core. {ECO:0000269|PubMed:11163187,
CC       ECO:0000269|PubMed:12718880, ECO:0000269|PubMed:16209946,
CC       ECO:0000269|PubMed:16601204, ECO:0000269|PubMed:18066079}.
CC   -!- SUBUNIT: Found in a post-splicing messenger ribonucleoprotein (mRNP)
CC       complex. Core component of the mRNA splicing-dependent exon junction
CC       complex (EJC); the core complex contains CASC3, EIF4A3, MAGOH or
CC       MAGOHB, and RBM8A. The EJC core components EIF4A3 and the MAGOH-RBM8A
CC       dimer form a composite binding site for UPF3B which overlaps with the
CC       EJC binding site for WIBG (PubMed:16601204, PubMed:18066079,
CC       PubMed:23917022, PubMed:20479275). Interacts with EST1A, UPF2 and RBM8A
CC       (PubMed:12554878, PubMed:18066079, PubMed:15004547). Interacts with
CC       CPSF6 (PubMed:19864460). {ECO:0000269|PubMed:11113196,
CC       ECO:0000269|PubMed:11163187, ECO:0000269|PubMed:11546873,
CC       ECO:0000269|PubMed:11546874, ECO:0000269|PubMed:12554878,
CC       ECO:0000269|PubMed:12718880, ECO:0000269|PubMed:15004547,
CC       ECO:0000269|PubMed:16209946, ECO:0000269|PubMed:16601204,
CC       ECO:0000269|PubMed:18066079, ECO:0000269|PubMed:19864460,
CC       ECO:0000269|PubMed:20479275, ECO:0000269|PubMed:23917022}.
CC   -!- INTERACTION:
CC       Q9BZI7; P38919: EIF4A3; NbExp=9; IntAct=EBI-372780, EBI-299104;
CC       Q9BZI7; P61326: MAGOH; NbExp=7; IntAct=EBI-372780, EBI-299134;
CC       Q9BZI7; Q9Y5S9: RBM8A; NbExp=9; IntAct=EBI-372780, EBI-447231;
CC       Q9BZI7; Q92900: UPF1; NbExp=10; IntAct=EBI-372780, EBI-373471;
CC       Q9BZI7; Q9HAU5: UPF2; NbExp=8; IntAct=EBI-372780, EBI-372073;
CC       Q9BZI7-2; P61326: MAGOH; NbExp=2; IntAct=EBI-15674130, EBI-299134;
CC       Q9BZI7-2; Q9HAU5: UPF2; NbExp=7; IntAct=EBI-15674130, EBI-372073;
CC       Q9BZI7-2; Q9H1J1: UPF3A; NbExp=2; IntAct=EBI-15674130, EBI-521530;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Shuttling between the
CC       nucleus and the cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BZI7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BZI7-2; Sequence=VSP_012963;
CC   -!- TISSUE SPECIFICITY: Expressed in testis, uterus, prostate, heart,
CC       muscle, brain, spinal cord and placenta. {ECO:0000269|PubMed:11113196}.
CC   -!- DISEASE: Mental retardation, X-linked, syndromic, 14 (MRXS14)
CC       [MIM:300676]: A disorder characterized by significantly below average
CC       general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       MRXS14 patients manifest mental retardation associated with other
CC       variable signs such as autistic features, slender build, poor
CC       musculature, long, thin face, high-arched palate, high nasal bridge,
CC       and pectus deformities. {ECO:0000269|PubMed:17704778}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the RENT3 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY013251; AAG48511.1; -; mRNA.
DR   EMBL; AF318576; AAG60691.1; -; mRNA.
DR   EMBL; CH471161; EAW89842.1; -; Genomic_DNA.
DR   EMBL; CH471161; EAW89844.1; -; Genomic_DNA.
DR   EMBL; CH471161; EAW89845.1; -; Genomic_DNA.
DR   EMBL; CH471161; EAW89846.1; -; Genomic_DNA.
DR   EMBL; BC121017; AAI21018.1; -; mRNA.
DR   CCDS; CCDS14587.1; -. [Q9BZI7-2]
DR   CCDS; CCDS14588.1; -. [Q9BZI7-1]
DR   RefSeq; NP_075386.1; NM_023010.3. [Q9BZI7-2]
DR   RefSeq; NP_542199.1; NM_080632.2. [Q9BZI7-1]
DR   PDB; 1UW4; X-ray; 1.95 A; A/C=50-140.
DR   PDB; 2XB2; X-ray; 3.40 A; G/U=424-483.
DR   PDBsum; 1UW4; -.
DR   PDBsum; 2XB2; -.
DR   SMR; Q9BZI7; -.
DR   BioGRID; 122396; 63.
DR   CORUM; Q9BZI7; -.
DR   DIP; DIP-31143N; -.
DR   IntAct; Q9BZI7; 34.
DR   MINT; Q9BZI7; -.
DR   STRING; 9606.ENSP00000276201; -.
DR   iPTMnet; Q9BZI7; -.
DR   PhosphoSitePlus; Q9BZI7; -.
DR   BioMuta; UPF3B; -.
DR   DMDM; 60390643; -.
DR   EPD; Q9BZI7; -.
DR   jPOST; Q9BZI7; -.
DR   MassIVE; Q9BZI7; -.
DR   MaxQB; Q9BZI7; -.
DR   PaxDb; Q9BZI7; -.
DR   PeptideAtlas; Q9BZI7; -.
DR   PRIDE; Q9BZI7; -.
DR   ProteomicsDB; 79849; -. [Q9BZI7-1]
DR   ProteomicsDB; 79850; -. [Q9BZI7-2]
DR   Antibodypedia; 464; 95 antibodies.
DR   Ensembl; ENST00000276201; ENSP00000276201; ENSG00000125351. [Q9BZI7-1]
DR   Ensembl; ENST00000345865; ENSP00000245418; ENSG00000125351. [Q9BZI7-2]
DR   GeneID; 65109; -.
DR   KEGG; hsa:65109; -.
DR   UCSC; uc004erz.3; human. [Q9BZI7-1]
DR   CTD; 65109; -.
DR   DisGeNET; 65109; -.
DR   GeneCards; UPF3B; -.
DR   HGNC; HGNC:20439; UPF3B.
DR   HPA; ENSG00000125351; Low tissue specificity.
DR   MalaCards; UPF3B; -.
DR   MIM; 300298; gene.
DR   MIM; 300676; phenotype.
DR   neXtProt; NX_Q9BZI7; -.
DR   OpenTargets; ENSG00000125351; -.
DR   Orphanet; 323; NON RARE IN EUROPE: FG syndrome phenotypic spectrum.
DR   Orphanet; 776; X-linked intellectual disability with marfanoid habitus.
DR   Orphanet; 777; X-linked non-syndromic intellectual disability.
DR   PharmGKB; PA128394708; -.
DR   VEuPathDB; HostDB:ENSG00000125351.10; -.
DR   eggNOG; KOG1295; Eukaryota.
DR   GeneTree; ENSGT00390000017146; -.
DR   HOGENOM; CLU_041202_1_0_1; -.
DR   InParanoid; Q9BZI7; -.
DR   OMA; DRCPEKE; -.
DR   OrthoDB; 737663at2759; -.
DR   PhylomeDB; Q9BZI7; -.
DR   TreeFam; TF316034; -.
DR   PathwayCommons; Q9BZI7; -.
DR   Reactome; R-HSA-159236; Transport of Mature mRNA derived from an Intron-Containing Transcript.
DR   Reactome; R-HSA-72163; mRNA Splicing - Major Pathway.
DR   Reactome; R-HSA-72187; mRNA 3'-end processing.
DR   Reactome; R-HSA-73856; RNA Polymerase II Transcription Termination.
DR   Reactome; R-HSA-9010553; Regulation of expression of SLITs and ROBOs.
DR   Reactome; R-HSA-975957; Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC).
DR   SIGNOR; Q9BZI7; -.
DR   BioGRID-ORCS; 65109; 22 hits in 640 CRISPR screens.
DR   EvolutionaryTrace; Q9BZI7; -.
DR   GeneWiki; UPF3B; -.
DR   GenomeRNAi; 65109; -.
DR   Pharos; Q9BZI7; Tbio.
DR   PRO; PR:Q9BZI7; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9BZI7; protein.
DR   Bgee; ENSG00000125351; Expressed in sural nerve and 221 other tissues.
DR   ExpressionAtlas; Q9BZI7; baseline and differential.
DR   Genevisible; Q9BZI7; HS.
DR   GO; GO:0034451; C:centriolar satellite; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0035145; C:exon-exon junction complex; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0003729; F:mRNA binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0017056; F:structural constituent of nuclear pore; NAS:UniProtKB.
DR   GO; GO:0031124; P:mRNA 3'-end processing; TAS:Reactome.
DR   GO; GO:0006406; P:mRNA export from nucleus; TAS:Reactome.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; TAS:Reactome.
DR   GO; GO:0000184; P:nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; IDA:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB.
DR   GO; GO:0006405; P:RNA export from nucleus; TAS:Reactome.
DR   CDD; cd12728; RRM_like_Smg4_UPF3B; 1.
DR   Gene3D; 3.30.70.330; -; 1.
DR   IDEAL; IID00251; -.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR039722; Upf3.
DR   InterPro; IPR005120; UPF3_dom.
DR   InterPro; IPR034979; UPF3B_RRM-like.
DR   PANTHER; PTHR13112; PTHR13112; 1.
DR   Pfam; PF03467; Smg4_UPF3; 1.
DR   SUPFAM; SSF54928; SSF54928; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Disease variant;
KW   Mental retardation; Methylation; mRNA transport;
KW   Nonsense-mediated mRNA decay; Nucleus; Phosphoprotein; Reference proteome;
KW   RNA-binding; Transport.
FT   CHAIN           1..483
FT                   /note="Regulator of nonsense transcripts 3B"
FT                   /id="PRO_0000215297"
FT   REGION          30..255
FT                   /note="Necessary for interaction with UPF2"
FT   REGION          52..57
FT                   /note="Binds to UPF2"
FT   REGION          424..483
FT                   /note="Sufficient for association with EJC core"
FT                   /evidence="ECO:0000269|PubMed:20479275"
FT   REGION          430..447
FT                   /note="Necessary for interaction with RBM8A and for
FT                   activating NMD"
FT   MOD_RES         169
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         198
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         310
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         447
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   VAR_SEQ         270..282
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11163187,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_012963"
FT   VARIANT         160
FT                   /note="Y -> D (in MRXS14; dbSNP:rs122468182)"
FT                   /evidence="ECO:0000269|PubMed:17704778"
FT                   /id="VAR_037666"
FT   MUTAGEN         52
FT                   /note="K->E: Abolishes interaction with UPF2."
FT                   /evidence="ECO:0000269|PubMed:15004547"
FT   MUTAGEN         53..58
FT                   /note="VVIRRL->AVARRA: Abolishes interaction with UPF2."
FT                   /evidence="ECO:0000269|PubMed:11113196"
FT   MUTAGEN         56
FT                   /note="R->E: Does not abolish interaction with UPF2."
FT                   /evidence="ECO:0000269|PubMed:15004547"
FT   MUTAGEN         117..119
FT                   /note="YVF->DVD: Abolishes interaction with UPF2."
FT                   /evidence="ECO:0000269|PubMed:11113196"
FT   MUTAGEN         430
FT                   /note="R->A: Reduces NMD."
FT                   /evidence="ECO:0000269|PubMed:12718880"
FT   MUTAGEN         432
FT                   /note="R->A: Reduces NMD."
FT                   /evidence="ECO:0000269|PubMed:12718880,
FT                   ECO:0000269|PubMed:16601204"
FT   MUTAGEN         434..447
FT                   /note="Missing: Abolishes NMD."
FT                   /evidence="ECO:0000269|PubMed:12718880"
FT   MUTAGEN         434
FT                   /note="K->A: Reduces NMD."
FT                   /evidence="ECO:0000269|PubMed:12718880"
FT   MUTAGEN         435
FT                   /note="D->A: Reduces NMD."
FT                   /evidence="ECO:0000269|PubMed:12718880"
FT   MUTAGEN         436
FT                   /note="R->A: Impairs association with EJC."
FT                   /evidence="ECO:0000269|PubMed:12718880,
FT                   ECO:0000269|PubMed:20479275"
FT   MUTAGEN         436
FT                   /note="R->A: Reduces NMD."
FT                   /evidence="ECO:0000269|PubMed:12718880,
FT                   ECO:0000269|PubMed:20479275"
FT   MUTAGEN         441
FT                   /note="L->F: Reduces NMD."
FT                   /evidence="ECO:0000269|PubMed:12718880"
FT   MUTAGEN         442
FT                   /note="Y->A: Impairs association with EJC."
FT                   /evidence="ECO:0000269|PubMed:20479275"
FT   MUTAGEN         447
FT                   /note="R->E: Abolishes NMD; when associated with E-449 and
FT                   E-451."
FT                   /evidence="ECO:0000269|PubMed:20479275"
FT   MUTAGEN         449
FT                   /note="R->E: Abolishes NMD; when associated with E-447 and
FT                   E-451."
FT                   /evidence="ECO:0000269|PubMed:20479275"
FT   MUTAGEN         451
FT                   /note="R->E: Abolishes NMD; when associated with E-447 and
FT                   E-449."
FT                   /evidence="ECO:0000269|PubMed:20479275"
FT   CONFLICT        358
FT                   /note="R -> H (in Ref. 4; AAI21018)"
FT                   /evidence="ECO:0000305"
FT   STRAND          52..58
FT                   /evidence="ECO:0007744|PDB:1UW4"
FT   HELIX           64..71
FT                   /evidence="ECO:0007744|PDB:1UW4"
FT   STRAND          77..85
FT                   /evidence="ECO:0007744|PDB:1UW4"
FT   STRAND          95..104
FT                   /evidence="ECO:0007744|PDB:1UW4"
FT   HELIX           105..114
FT                   /evidence="ECO:0007744|PDB:1UW4"
FT   STRAND          118..120
FT                   /evidence="ECO:0007744|PDB:1UW4"
FT   STRAND          126..128
FT                   /evidence="ECO:0007744|PDB:1UW4"
FT   STRAND          130..133
FT                   /evidence="ECO:0007744|PDB:1UW4"
FT   TURN            433..435
FT                   /evidence="ECO:0007744|PDB:2XB2"
SQ   SEQUENCE   483 AA;  57762 MW;  F5A8A395783D1A69 CRC64;
     MKEEKEHRPK EKRVTLLTPA GATGSGGGTS GDSSKGEDKQ DRNKEKKEAL SKVVIRRLPP
     TLTKEQLQEH LQPMPEHDYF EFFSNDTSLY PHMYARAYIN FKNQEDIILF RDRFDGYVFL
     DNKGQEYPAI VEFAPFQKAA KKKTKKRDTK VGTIDDDPEY RKFLESYATD NEKMTSTPET
     LLEEIEAKNR ELIAKKTTPL LSFLKNKQRM REEKREERRR REIERKRQRE EERRKWKEEE
     KRKRKDIEKL KKIDRIPERD KLKDEPKIKV HRFLLQAVNQ KNLLKKPEKG DEKELDKREK
     AKKLDKENLS DERASGQSCT LPKRSDSELK DEKPKRPEDE SGRDYRERER EYERDQERIL
     RERERLKRQE EERRRQKERY EKEKTFKRKE EEMKKEKDTL RDKGKKAEST ESIGSSEKTE
     KKEEVVKRDR IRNKDRPAMQ LYQPGARSRN RLCPPDDSTK SGDSAAERKQ ESGISHRKEG
     GEE
//
